From: “No generics, Doctor!” The perspective of general practitioners in two French regions
N | % | 95% CI | |
---|---|---|---|
What do you think are the advantages of generics? (Several possible responses) | |||
Reduced cost of medicines | 258 | 81.6 | 78.7–84.3 |
Advantages for the health insurance regime | 38 | 12.0 | 9.9–14.6 |
Control of health expenditure | 29 | 9.2 | 7.2–11.5 |
Coherence of prescribing by INNa | 18 | 5.7 | 4.2–7.6 |
Advantages for the patients | 6 | 1.9 | 1.1–3.2 |
Equivalent to the originator | 6 | 1.9 | 1.1–3.2 |
Efficacy equivalent to the originator | 5 | 1.6 | 0.9–2.8 |
Safety equivalent to the originator | 0 | 0 | 0 |
Identical quality to the originator | 0 | 0 | 0 |
What do you think are the drawbacks of generics? (Several possible responses) | |||
Patients may be confused by changes in presentation | 148 | 46.8 | 43.2–50.5 |
Presentation and dosage form differ between laboratories for the same molecule | 139 | 44.0 | 40.4–47.6 |
Patients report more adverse effects | 117 | 37.0 | 33.6–40.6 |
Patients refuse generics | 81 | 25.6 | 22.6–28.9 |
Patients report that generics are less effective | 75 | 23.7 | 20.8–27.0 |
Personal doubt as to equivalence | 66 | 20.9 | 18.1–24.0 |
Poorer treatment compliance by patients | 63 | 19.9 | 17.2–23.0 |
Complexity of prescribing by INN a/name is difficult for the patient | 52 | 16.5 | 13.9–19.3 |
Excipients differ between generics and from the originator | 42 | 13.3 | 11.0–15.9 |
Personal doubts as to efficacy | 35 | 11.1 | 9.0–13.6 |
Doubtful quality | 32 | 10.1 | 8.1–11.5 |
Negative impact on the physician-patient relationship | 28 | 8.9 | 7.0–11.1 |
More frequent allergic manifestations | 25 | 7.9 | 6.2–10.1 |
Personal doubt as to safety of generics | 23 | 7.3 | 5.6–9.4 |
Doubtful manufacturing origin | 20 | 6.3 | 4.8–8.3 |
Complexity of prescribing by INN a/name is difficult for the practitioner | 18 | 5.7 | 4.2–7.6 |
Generics infringe freedom of prescription | 13 | 4.1 | 2.9–5.8 |
Unacceptable demand by the state or health insurance regime | 11 | 3.5 | 2.4–5.1 |
Poor presentation of generics compared with originators | 7 | 2.2 | 1.4–3.6 |